Apamin

none in common use; sometimes written as the SK channel blocker "apamin" without qualification

Cognitive & neuro
Awaiting medical reviewEN ES DE FR PT ZH+ Follow for updates

1What it is

Apamin is one of the smallest neurotoxins known — eighteen amino acids, held in a compact fold by two disulfide bridges. It was isolated from honeybee venom in the 1960s and its sequence determined shortly after; the name derives from Apis.

Its importance is almost entirely as a reagent. When apamin was found to block a specific class of potassium channel and nothing much else, it became the defining pharmacological tool for that channel family. The small-conductance calcium-activated potassium channels are still routinely identified in experiments as "apamin-sensitive", and a large part of what is known about how neurons control their own firing rate came from applying apamin and observing what disappeared.

It should not be confused with melittin (#142), the much more abundant membrane-lysing peptide that causes most of the pain and tissue damage of a bee sting. Apamin is present in smaller amounts and acts quite differently — it is a neurotoxin rather than a cytolytic agent. Both are present in the bee venom preparations used in apitherapy, which is discussed in the safety notes below.


2How it's thought to work

SK channel blockade. Apamin binds the outer vestibule of SK channels and blocks ion flow, with high potency at SK2, lower at SK1 and SK3, and essentially none at the large-conductance BK channel. SK channels open in response to intracellular calcium rather than voltage.
Loss of the afterhyperpolarisation. After a neuron fires, calcium entry opens SK channels, which hyperpolarise the membrane and impose a pause before the next spike — the medium afterhyperpolarisation. Apamin removes that brake, so neurons fire in bursts rather than at a regular rate. This single effect explains most of apamin's actions, therapeutic-sounding and toxic alike.
Central effects and seizures. In the central nervous system removal of the brake raises excitability; apamin given centrally to rodents causes hyperactivity and convulsions. It crosses the blood–brain barrier poorly but not negligibly, which is why systemic doses can produce central signs.
Smooth muscle and endothelium. Apamin-sensitive channels contribute to non-adrenergic non-cholinergic relaxation in gut smooth muscle, and, in combination with charybdotoxin, apamin is the standard way to demonstrate endothelium-derived hyperpolarisation in blood vessels.
Cardiac repolarisation. SK channels contribute to atrial and, under some conditions, ventricular repolarisation; apamin is the tool used to show it, and this work has raised interest in SK channels as an antiarrhythmic target.
A bee venom peptide that blocks small-conductance calcium-activated potassium channels. Used as a laboratory tool; it is a neurotoxin, not a treatment.Schematic — not to scale

3What the research shows

Graded D (but foundational)

Definition of the SK channel family

The entire operational definition of SK channels rests on apamin sensitivity, established across decades of electrophysiology in isolated neurons, muscle and heterologous expression systems. This is in-vitro evidence by grade, and it is nonetheless some of the best-replicated pharmacology in the field.

Learning and memory in rodents

Blocking SK channels increases neuronal excitability and enhances long-term potentiation, and apamin has been reported to improve performance in several rodent learning tasks (Messier 1991, Brain Res, and subsequent work; Stackman 2002, J Neurosci, on SK2 and hippocampal plasticity). The reverse manipulation — SK channel activation — impairs learning. This is a genuine and reproducible line of evidence, and it is also the source of a great deal of overstatement online. "Apamin improves memory in mice at carefully controlled central doses" is not the same claim as "apamin is a cognitive enhancer". [4][5]
Graded C/D

Gut motility

Apamin-sensitive inhibitory junction potentials are a well-characterised component of enteric neurotransmission in isolated tissue from several species.
Graded C/D

Vascular and cardiac electrophysiology

Apamin plus charybdotoxin is the standard combination used to isolate endothelium-derived hyperpolarisation. Cardiac work implicates SK channels in atrial repolarisation and in arrhythmia in failing hearts.
Graded B (and poor quality)

Bee venom therapy / apitherapy

Whole bee venom, which contains apamin among many other components, has been studied in small trials for arthritis, multiple sclerosis and pain. A randomised trial of bee venom therapy in multiple sclerosis found no benefit (Wesselius 2005, Neurology). Trials of bee venom acupuncture are generally small, heterogeneous and at high risk of bias. None of this is evidence about apamin specifically, and it is frequently misrepresented as such. [6]
Not gradednone

Human therapeutic data

Apamin has never been developed as a drug and there is no human trial of purified apamin for any indication. There is no plausible reason to expect one: a selective blocker of neuronal firing brakes is a convulsant.

4Reported side effects and interactions

Literature-reported

Literature (animal toxicology). apamin is a lethal neurotoxin in rodents, with reported mouse lethal doses in the low milligram-per-kilogram range systemically and far lower by central routes †. Signs are hyperexcitability, tremor, ataxia and convulsions progressing to death.

Literature (human exposure — bee sting and apitherapy). the clinically important human exposures are stings and deliberate bee venom therapy. Local pain, swelling and inflammation are largely melittin-driven. The serious risk is anaphylaxis, which is a hypersensitivity reaction to venom allergens and can be fatal on a single sting in a sensitised person. Massive envenomation from hundreds of stings produces rhabdomyolysis, haemolysis, acute kidney injury and multi-organ failure. Serum sickness, encephalopathy and acute kidney injury have been reported after bee venom therapy.

Community-reported

Community use: essentially none documented for purified apamin. Bee venom products used in apitherapy and cosmetics do have consumer use, but they are whole-venom preparations and the apamin content is incidental. Self-administration of purified apamin would be dangerous and would achieve nothing therapeutic — its pharmacological action is to remove a brake on nerve firing, which at systemic doses means convulsions, and the rodent cognitive findings were produced by controlled central delivery in the laboratory.

Theoretical. central SK blockade would be expected to lower seizure threshold; cardiac SK blockade could be pro- or antiarrhythmic depending on context.

Interactions. none established in humans. Pro-convulsant effects would be expected to be additive with anything else lowering seizure threshold.

Markers researchers commonly monitor

No compound-specific markers are established and there is no human administration to monitor. The relevant measures in the literature are experimental, or clinical in the envenomation setting: No markers apply to purified apamin, because no human takes it.

MarkerWhy it's watched
Afterhyperpolarisation amplitude and firing pattern in patch-clamp recordingsthe direct measure of target engagement, and the basis of the channel's definition.
EEG and seizure observation in animal studiesthe dose-limiting toxicity.
For massive bee envenomation (clinical): creatine kinase and myoglobin for rhabdomyolysis, haptoglobin and LDH for haemolysis, creatinine and urine output for acute kidney injury, liver enzymes, coagulation screenthis is the established monitoring for a sting emergency, and the only context in which laboratory monitoring of bee venom exposure is meaningful.
Serum tryptasein suspected anaphylaxis, taken within hours, to confirm mast cell activation.

Free for everyone. Safety information is never behind a paywall.


5Research context and safety notes

Apamin is a laboratory neurotoxin and a reference pharmacological tool. The constraints that keep it in that category: - It is a convulsant. The mechanism that makes apamin interesting — removing the afterhyperpolarisation that limits neuronal firing — is a mechanism for producing seizures. There is no dose window in which this becomes a therapeutic effect systemically. - Potency and lethality. It is lethal to rodents at low milligram-per-kilogram systemic doses and at far smaller central doses. Laboratory quantities are therefore quantities that matter. - Route. The rodent cognitive and electrophysiological effects were produced by intracerebroventricular injection, direct application to tissue, or carefully titrated systemic dosing in anaesthetised animals. None of these have a self-administration equivalent. - Anaphylaxis risk from the source material. Bee venom is a potent allergen. Anyone handling whole venom, or receiving bee venom therapy, faces a real risk of a fatal hypersensitivity reaction independent of any pharmacological effect. No preparation, solvent, concentration or storage guidance is given here.


6Commonly studied alongside

Melittin (#142), the other major bee venom peptide and the one with actual consumer exposure; charybdotoxin and iberiotoxin (scorpion-venom potassium channel blockers used alongside apamin to separate SK from BK and IK channels); 1-EBIO and NS309 as SK channel activators used to make the opposite manipulation; whole bee venom preparations in the apitherapy literature.

Informational cross-links. Not stack recommendations.


7Regulatory status by region

RegionStatus (checked —)
United StatesNot FDA-approved. Purified apamin is a research chemical. Bee venom is used in licensed allergen immunotherapy products and in unregulated cosmetic and apitherapy products
European UnionNot authorised as a medicine; bee venom allergen extracts are regulated products. Apamin itself research-only
United KingdomNot licensed
AustraliaNot approved
South AfricaNot registered
SportNot listed by WADA; S0 would apply in principle to any non-approved substance. No performance application — the pharmacology is convulsant

8Open questions

  • Are SK channels a viable drug target in either direction — activators for epilepsy and ataxia, modulators for atrial fibrillation — given that blockade is convulsant?
  • Do the rodent learning findings reflect a genuine cognitive mechanism or an artefact of global hyperexcitability?
  • What is apamin's actual function in the venom, given that it is a poor contributor to sting pain and present in small amounts?
  • Can subtype-selective SK modulators separate the cardiac, enteric and central actions?

9References

  1. 1Habermann E (1972). Bee and wasp venoms. Science. PubMed · DOI
  2. 2Blatz AL, Magleby KL (1986). Single apamin-blocked Ca-activated K+ channels of small conductance in cultured rat skeletal muscle. Nature. PubMed · DOI
  3. 3Köhler M et al. (1996). Small-conductance, calcium-activated potassium channels from mammalian brain. Science. PubMed · DOI
  4. 4Messier C et al. (1991). Effect of apamin, a toxin that inhibits Ca2+-dependent K+ channels, on learning and memory processes. Brain Res. PubMed · DOI
  5. 5Stackman RW et al. (2002). Small conductance Ca2+-activated K+ channels modulate synaptic plasticity and memory encoding. J Neurosci. PubMed · DOI
  6. 6Wesselius T et al. (2005). A randomized crossover study of bee sting therapy for multiple sclerosis. Neurology. PubMed · DOI
  7. 7Lamy C et al. (2010). Allosteric block of KCa2 channels by apamin. J Biol Chem. PubMed · DOI

† Being confirmed by our reviewers against current sources.


10Community

Threads and protocols are visible to members. Joining is free.

Self-reported side effects Phase 2

Not enough data yet. 0 of the 50 members needed have logged this compound for 4+ weeks. We don't show anything below 50, so no one can be identified.

11Page history

31 Oct 2026Profile published — awaiting medical review

Licensed CC BY-NC-SA 4.0. Found an error? Report it · Editorial standards — corrections are logged here.